AAPL343.20-0.26 (-0.08%) ▼|ABBV283.13-2.29 (-0.80%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.90+7.22 (+3.14%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.05-2.22 (-1.20%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.37+2.78 (+0.88%) ▲|BA191.51+1.30 (+0.68%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.83-9.56 (-0.84%) ▼|BMY58.84-0.91 (-1.52%) ▼|BNY142.41-0.89 (-0.62%) ▼|BRK-B532.47+0.45 (+0.08%) ▲|C121.72-2.54 (-2.04%) ▼|CAT725.77-4.99 (-0.68%) ▼|CL93.40-0.71 (-0.75%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.86-1.88 (-0.93%) ▼|COP145.21-1.30 (-0.89%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.46+1.76 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.34%) ▲|CVX224.48-0.51 (-0.23%) ▼|DE627.30-14.56 (-2.27%) ▼|DHR224.39-4.65 (-2.03%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK119.26-2.21 (-1.82%) ▼|EMR160.52-0.95 (-0.59%) ▼|FDX293.81+0.26 (+0.09%) ▲|GD341.40-2.83 (-0.82%) ▼|GE311.34-2.49 (-0.79%) ▼|GEV908.35-12.85 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.72-1.24 (-1.48%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.79-5.47 (-0.62%) ▼|HD309.99+0.36 (+0.12%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.36+4.22 (+1.82%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.96-1.60 (-0.63%) ▼|JPM333.63-6.09 (-1.79%) ▼|KO93.44-0.47 (-0.50%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.40-16.63 (-1.32%) ▼|LMT548.45-3.64 (-0.66%) ▼|LOW195.90-1.48 (-0.75%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.27-1.15 (-0.19%) ▼|MCD242.63-0.34 (-0.14%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.74-2.01 (-2.12%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.10-2.65 (-1.61%) ▼|MO74.07-1.05 (-1.39%) ▼|MRK143.67-2.28 (-1.56%) ▼|MS178.49-2.08 (-1.15%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.18-1.62 (-2.03%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.22+0.09 (+0.24%) ▲|NOW145.35+3.38 (+2.38%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.63+1.40 (+1.09%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.43-0.15 (-0.51%) ▼|PG157.71-1.64 (-1.03%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM200.98-4.22 (-2.06%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.28-10.72 (-1.55%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|AAPL343.20-0.26 (-0.08%) ▼|ABBV283.13-2.29 (-0.80%) ▼|ABT104.06-0.83 (-0.79%) ▼|ACN236.90+7.22 (+3.14%) ▲|ADBE247.09+1.89 (+0.77%) ▲|AMAT413.11+3.82 (+0.93%) ▲|AMD538.05+9.30 (+1.76%) ▲|AMGN424.94-7.55 (-1.75%) ▼|AMT183.05-2.22 (-1.20%) ▼|AMZN262.45+12.45 (+4.98%) ▲|AVGO334.59+5.84 (+1.78%) ▲|AXP316.37+2.78 (+0.88%) ▲|BA191.51+1.30 (+0.68%) ▲|BAC50.39-0.84 (-1.64%) ▼|BKNG162.60-0.85 (-0.52%) ▼|BLK1,124.83-9.56 (-0.84%) ▼|BMY58.84-0.91 (-1.52%) ▼|BNY142.41-0.89 (-0.62%) ▼|BRK-B532.47+0.45 (+0.08%) ▲|C121.72-2.54 (-2.04%) ▼|CAT725.77-4.99 (-0.68%) ▼|CL93.40-0.71 (-0.75%) ▼|CMCSA21.90+0.00 (+0.00%) ▲|COF199.86-1.88 (-0.93%) ▼|COP145.21-1.30 (-0.89%) ▼|COST995.53+6.42 (+0.65%) ▲|CRM242.46+1.76 (+0.73%) ▲|CSCO106.50-0.89 (-0.83%) ▼|CVS92.68+0.32 (+0.34%) ▲|CVX224.48-0.51 (-0.23%) ▼|DE627.30-14.56 (-2.27%) ▼|DHR224.39-4.65 (-2.03%) ▼|DIS109.58-1.01 (-0.91%) ▼|DUK119.26-2.21 (-1.82%) ▼|EMR160.52-0.95 (-0.59%) ▼|FDX293.81+0.26 (+0.09%) ▲|GD341.40-2.83 (-0.82%) ▼|GE311.34-2.49 (-0.79%) ▼|GEV908.35-12.85 (-1.39%) ▼|GILD153.07-3.12 (-2.00%) ▼|GM82.72-1.24 (-1.48%) ▼|GOOG340.16+3.25 (+0.96%) ▲|GOOGL344.18+3.59 (+1.05%) ▲|GS875.79-5.47 (-0.62%) ▼|HD309.99+0.36 (+0.12%) ▲|HON209.98-1.43 (-0.68%) ▼|IBM236.36+4.22 (+1.82%) ▲|INTC92.03+2.18 (+2.43%) ▲|INTU325.62+0.47 (+0.14%) ▲|ISRG433.18+6.48 (+1.52%) ▲|JNJ253.96-1.60 (-0.63%) ▼|JPM333.63-6.09 (-1.79%) ▼|KO93.44-0.47 (-0.50%) ▼|LIN503.44+5.01 (+1.01%) ▲|LLY1,240.40-16.63 (-1.32%) ▼|LMT548.45-3.64 (-0.66%) ▼|LOW195.90-1.48 (-0.75%) ▼|LRCX272.20+8.26 (+3.13%) ▲|MA616.27-1.15 (-0.19%) ▼|MCD242.63-0.34 (-0.14%) ▼|MDLZ63.34-0.57 (-0.89%) ▼|MDT92.74-2.01 (-2.12%) ▼|META705.44-3.89 (-0.55%) ▼|MMM162.10-2.65 (-1.61%) ▼|MO74.07-1.05 (-1.39%) ▼|MRK143.67-2.28 (-1.56%) ▼|MS178.49-2.08 (-1.15%) ▼|MSFT533.52+4.47 (+0.84%) ▲|MU904.90+26.06 (+2.97%) ▲|NEE78.18-1.62 (-2.03%) ▼|NFLX69.85-0.68 (-0.96%) ▼|NKE37.22+0.09 (+0.24%) ▲|NOW145.35+3.38 (+2.38%) ▲|NVDA217.09+2.96 (+1.38%) ▲|ORCL129.63+1.40 (+1.09%) ▲|PEP133.57+2.08 (+1.58%) ▲|PFE29.43-0.15 (-0.51%) ▼|PG157.71-1.64 (-1.03%) ▼|PLTR194.15+8.12 (+4.36%) ▲|PM200.98-4.22 (-2.06%) ▼|QCOM173.53+1.42 (+0.83%) ▲|RTX192.11-1.81 (-0.93%) ▼|SBUX97.87+0.35 (+0.36%) ▲|SCHW89.58-2.38 (-2.59%) ▼|SO89.27-1.91 (-2.09%) ▼|SPG202.49-2.95 (-1.44%) ▼|T23.20-0.24 (-1.02%) ▼|TMO679.28-10.72 (-1.55%) ▼|TMUS156.09-3.01 (-1.89%) ▼|TSLA368.06+13.34 (+3.76%) ▲|TXN276.15-0.33 (-0.12%) ▼|UBER69.96-0.39 (-0.55%) ▼|UNH406.88+5.45 (+1.36%) ▲|UNP287.01-2.03 (-0.70%) ▼|UPS97.46-0.02 (-0.02%) ▼|USB57.85-0.88 (-1.50%) ▼|V402.92+0.31 (+0.08%) ▲|VZ44.15-0.64 (-1.43%) ▼|WFC81.80-2.07 (-2.47%) ▼|WMT118.70-0.11 (-0.09%) ▼|XOM178.28-0.70 (-0.39%) ▼|
18 C
New York
Monday, October 19, 2026

Tag: therapies

newssourceFORcompanycontentinformation1releasesmarket

OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors

— New Studies Expand Cesalatamig into Biomarker-driven Precision Immuno-oncology Strategies— Cesalatamig is Also Being Evaluated in Ongoing Phase 2 Studies in the United States and in...

IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy...

OptimUM-01 and OptimUM-02 data supports the broad potential of darovasertib plus crizotinib to drive meaningful clinical benefits for patients with metastatic uveal melanoma, irrespective...

Lilly’s Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative...

Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label...

AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe...

In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at...

WuXi Biologics at Festival of Biologics Basel 2026: Turning Scientific Complexity into Commercial Certainty

BASEL, Switzerland, Oct. 19, 2026 /PRNewswire/ -- More than 3,000 industry professionals gathered at Festival of Biologics Basel 2026 to exchange insights on the future...

Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.

Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy...

HISTOINDEX AND A*STAR PARTNER TO ADVANCE EARLY-STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASES

SINGAPORE, Oct. 19, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR),...

HISTOINDEX AND A*STAR PARTNER TO ADVANCE EARLY-STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASES

SINGAPORE, Oct. 18, 2026 /PRNewswire/ -- HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR),...

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical...

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse...

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line...

New Progress — XellSmart Unveiled Phase I Results of Off-the-Shelf Parkinson’s Disease Cell Therapy at MDS & Completed Blinded Phase II Enrollment

SEOUL, South Korea and SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- New clinical data for XellSmart's off-the-shelf cell therapy for Parkinson's Disease was presented at...

Abu Dhabi Health Delegation Concludes Inaugural Visit to China, Opening New Pathways to Advance AI, Precision Medicine and Next-Gen Therapies

ABU DHABI, UAE, Oct. 18, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the...

Abu Dhabi Health Delegation Concludes Inaugural Visit to China, Opening New Pathways to Advance AI, Precision Medicine and Next-Gen Therapies

ABU DHABI, UAE, Oct. 17, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers